Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 27.10.2025 1 Am J Epidemiol 6 Ann Oncol 4 Ann Surg Oncol 4 BMC Cancer 2 Br J Cancer 1 Breast Cancer 4 Breast Cancer Res 1 Breast Cancer Res Treat 1 Breast J 3 Cancer 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Res 1 Carcinogenesis 5 Clin Breast Cancer 1 Clin Cancer Res 1 Curr Treat Options Oncol 1 Eur J Surg Oncol 1 Eur Radiol 1 Int J Cancer 1 J Clin Oncol 2 Mod Pathol 1 N Engl J Med 2 Nature 5 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Epidemiol

1. MORLEY F, An A, Bea V, Tamimi RM, et al
   Evaluating the association between upstream perceived individual and neighborhood determinants of health and intensity of breast cancer screening.
   Am J Epidemiol. 2025 Oct 22:kwaf234. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. MAYER EL, Trapani D, Kim SE, Faggen M, et al
   TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer.
   Ann Oncol. 2025 Oct 17:S0923-7534(25)04932-4. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
3. MALORNI L, Tyekucheva S, Gombos A, Hasler-Strub U, et al
   Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
   Ann Oncol. 2025 Oct 16:S0923-7534(25)04963-4. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
4. HARBECK N, Modi S, Pusztai L, Ohno S, et al
   Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.
   Ann Oncol. 2025 Oct 18:S0923-7534(25)04968-3. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
5. MAYER EL, Bidard FC, Park YH, Janni W, et al
   Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.
   Ann Oncol. 2025 Oct 20:S0923-7534(25)04949-X. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
6. MAYER EL, Hlauschek D, Gnant M, O'Brien PJ, et al
   Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
   Ann Oncol. 2025 Oct 17:S0923-7534(25)04935-X. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
7. JOHNSTON S, Martin M, O'Shaughnessy J, Hegg R, et al
   Overall Survival with Abemaciclib in Early Breast Cancer.
   Ann Oncol. 2025 Oct 17:S0923-7534(25)04948-8. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

8. VETTER CD, Hoskin T, Olson C, Giridhar K, et al
   ASO Visual Abstract: Validation of the Performance of the Novel Prognostic Staging System for Overall Survival in De Novo Metastatic Breast Cancer and Demonstration of Performance for Cancer-Specific Outcomes.
   Ann Surg Oncol. 2025 Oct 22. doi: 10.1245/s10434-025-18350.
   PubMed        
   
   
9. ARIMA J, Chida K, Wu R, Taniguchi K, et al
   ASO Visual Abstract: ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in ER-Positive HER2-Negative Breast Cancer.
   Ann Surg Oncol. 2025 Oct 22. doi: 10.1245/s10434-025-18480.
   PubMed        
   
   
10. WAGNER BD, Rubin J, Lin IH, Raina J, et al
    Clinical Features, Microbial Epidemiology, and Recurrence Risk of Cellulitis in Breast Cancer-Related Lymphedema.
    Ann Surg Oncol. 2025 Oct 19. doi: 10.1245/s10434-025-18598.
    PubMed         Abstract available
    
    
11. KOBZEVA-HERZOG AJ, Palaniappan S, Jiangliu Y, Kraus E, et al
    A Multidisciplinary Breast Cancer Clinic Improves Time to Treatment at an Urban, Safety Net Hospital.
    Ann Surg Oncol. 2025 Oct 17. doi: 10.1245/s10434-025-18497.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. SONG Z, Ding M, Zang Q, Wang L, et al
    Association of reproductive and menstrual factors with the risk of breast cancer in women: a population-based study.
    BMC Cancer. 2025;25:1621.
    PubMed         Abstract available
    
    
13. AMIN A, U DA, Koteshwara P, P C S, et al
    A systematic literature review on mammography: deep learning techniques for breast cancer detection with global and Asian perspectives.
    BMC Cancer. 2025;25:1627.
    PubMed         Abstract available
    
    
14. DERISMAHAFI Z, Farhud D, Razavirad A, Muhammadnejad A, et al
    NRF2 expression level and estrogen function in BRCA1-mutated breast cancer.
    BMC Cancer. 2025;25:1622.
    PubMed         Abstract available
    
    
15. LI Y, Zhang Z, Liu X, Cheng Y, et al
    Integrative analysis identifies radiotherapy resistance-associated CAF subtypes shaping the tumor immune landscape in breast cancer.
    BMC Cancer. 2025;25:1603.
    PubMed         Abstract available
    
    

    
    Br J Cancer

16. FUJII T, Iwase T, Shen Y, Fukui J, et al
    Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer.
    Br J Cancer. 2025 Oct 18. doi: 10.1038/s41416-025-03197.
    PubMed         Abstract available
    
    
17. RUIZ DE AZUA G, Licaj I, Pinto S, Havas J, et al
    Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.
    Br J Cancer. 2025 Oct 21. doi: 10.1038/s41416-025-03238.
    PubMed         Abstract available
    
    

    
    Breast Cancer

18. SHIN Y, Shin K, Lee S, Son Y, et al
    Immune checkpoint inhibition in breast cancer: targeting PD-1/PD-L1 pathway for therapeutic advances.
    Breast Cancer. 2025 Oct 22. doi: 10.1007/s12282-025-01793.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

19. GUO Y, Chen M, Yuan Q, Huang J, et al
    Modulating phosphodiesterase-5 activity to suppress the immunosuppressive mechanisms of myeloid-derived suppressor cells in breast cancer.
    Breast Cancer Res. 2025;27:184.
    PubMed         Abstract available
    
    
20. CUI W, Fan M, Li L
    Morphological analysis of tumor microenvironment in HER2-positive breast cancer: predicting response to neoadjuvant chemotherapy on histopathological images.
    Breast Cancer Res. 2025;27:182.
    PubMed         Abstract available
    
    
21. PARK I, Shin SJ, Go H, Ko J, et al
    Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex Immunofluorescence.
    Breast Cancer Res. 2025;27:181.
    PubMed         Abstract available
    
    
22. NOROUZI F, Eini P, Tahmasebi S
    The role of NETosis in breast cancer: mechanistic insights and biomarker potential.
    Breast Cancer Res. 2025;27:180.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

23. YOON KH, Yoon Y, Jeong S, Kang J, et al
    Impact of obesity on breast cancer recurrence by menopausal status and subtype: a retrospective cohort study.
    Breast Cancer Res Treat. 2025 Oct 21. doi: 10.1007/s10549-025-07823.
    PubMed         Abstract available
    
    

    
    Breast J

24. PUSCZ F, Ahmadi N, Schmidt SV, Reinkemeier F, et al
    Characteristics, Outcomes, and Risk Factors in Primary and Secondary Angiosarcoma: A Retrospective Cohort Study.
    Breast J. 2025;2025:7158762.
    PubMed         Abstract available
    
    

    
    Cancer

25. MOEN EL, Loehrer AP, Onega T
    Regionalization of breast cancer surgical care: Moving beyond a one-size-fits-all strategy.
    Cancer. 2025;131:e70142.
    PubMed        
    
    
26. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
    Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
    Cancer. 2025;131 Suppl 2.
    PubMed         Abstract available
    
    
27. BARBER LE, Maliniak ML, Miller-Kleinhenz JM, Moubadder L, et al
    Understanding the role of neighborhood deprivation in racial disparities in triple-negative breast cancer.
    Cancer. 2025;131:e70138.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

28. EL MOHEB M, Shen C, Rabinovich E, Kim S, et al
    Predicting Health-Related Quality of Life Trajectories in Elderly Breast Cancer Patients: From Pre-Diagnosis to Long-Term Follow-up.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Res

29. EL LAITHY Y, Abreu De Oliveira WA, Pabba A, Qualizza A, et al
    Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State.
    Cancer Res. 2025 Oct 21. doi: 10.1158/0008-5472.CAN-24-4165.
    PubMed         Abstract available
    
    
30. CHENOWETH AM, Cheung A, Chauhan J, Adams R, et al
    An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer.
    Cancer Res. 2025 Oct 23:OF1-OF20. doi: 10.1158/0008-5472.CAN-24-3174.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

31. KO YS, Jin H, Lee SE, Won JY, et al
    A2AR-phospho-STAT1 (Y701)-HLA-E axis as a potential immune modulatory pathway in radiotherapy-resistant triple negative breast cancer.
    Carcinogenesis. 2025 Oct 22:bgaf069. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

32. MOLONEY-LINEEN C, O'Connor M, O'Leary C, Hadia P, et al
    Dose Adjusted Neoadjuvant Paclitaxel, Carboplatin, Trastuzumab and Pertuzumab in Women With HER2 Positive Early Breast Cancer.
    Clin Breast Cancer. 2025 Sep 25:S1526-8209(25)00283.
    PubMed         Abstract available
    
    
33. MARTA GN, Pereira AAL, Anjos CHD, Linck RDM, et al
    Healthcare-Related Determinants of Breast Cancer Prognosis in Sao Paulo, Brazil: A Population-Based Cohort.
    Clin Breast Cancer. 2025 Sep 25:S1526-8209(25)00285.
    PubMed         Abstract available
    
    
34. LEE S, Jeong H, Shin E, Lee SB, et al
    Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy.
    Clin Breast Cancer. 2025 Sep 19:S1526-8209(25)00275.
    PubMed         Abstract available
    
    
35. BOZORGPOUR R
    From Molecules to Medicine: Molecular Dynamics and Docking in Breast Cancer Therapeutics.
    Clin Breast Cancer. 2025 Sep 18:S1526-8209(25)00277.
    PubMed         Abstract available
    
    
36. NATANIA S A
    Letter to the Editor Regarding the Article "Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label
    Clin Breast Cancer. 2025 Sep 21:S1526-8209(25)00281.
    PubMed        
    
    

    
    Clin Cancer Res

37. TESCH ME, Zheng Y, Guzman-Arocho YD, Collins LC, et al
    Association of tumor-infiltrating lymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive breast cancer.
    Clin Cancer Res. 2025 Oct 21. doi: 10.1158/1078-0432.CCR-25-0948.
    PubMed         Abstract available
    
    

    
    Curr Treat Options Oncol

38. CHATTOPADHYAY A, Goyal F, Sehrawat A, Sidhu IS, et al
    Correction to: Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.
    Curr Treat Options Oncol. 2025 Oct 22. doi: 10.1007/s11864-025-01359.
    PubMed        
    
    

    
    Eur J Surg Oncol

39. CLIFFORD JT, Ryan OK, Donnelly M, Davey M, et al
    From obesity to oncology; bariatric surgery and the impact on breast cancer- what is the link? - A systematic review and meta-analysis.
    Eur J Surg Oncol. 2025;51:110478.
    PubMed         Abstract available
    
    

    
    Eur Radiol

40. ZHANG T, Liang X, Mann RM
    Multimodal artificial intelligence in breast cancer: towards integrated prediction and personalized care.
    Eur Radiol. 2025 Oct 22. doi: 10.1007/s00330-025-12085.
    PubMed        
    
    

    
    Int J Cancer

41. DAUGS K, Brandes D, Yasin L, Anwar A, et al
    Germline variants observed in pediatric cancer patients related to hereditary breast and ovarian cancer in adults.
    Int J Cancer. 2025 Aug 26. doi: 10.1002/ijc.70097.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

42. GUPTA S, Nair N, Hawaldar RW, Joshi S, et al
    Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2025 Oct 20:JCO2501023. doi: 10.1200/JCO-25-01023.
    PubMed         Abstract available
    
    

    
    Mod Pathol

43. BADVE S, White JS, Sapunar F, Thoele K, et al
    Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.
    Mod Pathol. 2025;38:100813.
    PubMed         Abstract available
    
    
44. ANH NGUYEN TT, Zhang J, Iqbal J, Ahmed SS, et al
    Proposing New Criteria for Classification of Benign Fibroepithelial Lesions Based on Clinicopathologic Evaluations of 507 Cases with Clinical Outcome.
    Mod Pathol. 2025;38:100812.
    PubMed         Abstract available
    
    

    
    N Engl J Med

45. CORTES J, Punie K, Barrios C, Hurvitz SA, et al
    Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2025 Oct 19. doi: 10.1056/NEJMoa2511734.
    PubMed         Abstract available
    
    

    
    Nature

46. VARTAN S
    Breastfeeding boosts immune cells that protect against breast cancer.
    Nature. 2025 Oct 20. doi: 10.1038/d41586-025-03419.
    PubMed        
    
    
47. VIRASSAMY B, Caramia F, Savas P, Harris MA, et al
    Parity and lactation induce T cell mediated breast cancer protection.
    Nature. 2025 Oct 20. doi: 10.1038/s41586-025-09713.
    PubMed         Abstract available
    
    

    
    PLoS One

48. SRIKUMMOON P, Traisathit P, Onchan W, Ditsatham C, et al
    The recurrence and mortality risk in Luminal A breast cancer patients who lived in high pollution area.
    PLoS One. 2025;20:e0335140.
    PubMed         Abstract available
    
    
49. SAH AK, Prajapati R, Pathak N, Panta S, et al
    Assessment of drug-related problems among breast cancer patients in a cancer specialty center in Nepal.
    PLoS One. 2025;20:e0334703.
    PubMed         Abstract available
    
    
50. FONSECA-BENITEZ AV, Diaz-Baez D, Guevara-Pulido J, Rondon-Lagos M, et al
    Prognostic value of FOXA1 in estrogen receptor-negative breast cancer: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0332516.
    PubMed         Abstract available
    
    
51. CHIODI A, Pelucchi P, Mosca E
    Analysis of intracellular and intercellular crosstalk from omics data.
    PLoS One. 2025;20:e0334981.
    PubMed         Abstract available
    
    
52. ZHANG XR, Yuan SS, Hu JJ, Chen QQ, et al
    An exploratory study on predicting HER2-positive expression status of breast cancer using ultrasound radiomics combined with machine learning models.
    PLoS One. 2025;20:e0334909.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

53. PIERCE SB, Kortbawi H, Gulsuner S, Mandell JB, et al
    Genetic regulation of the estrogen receptor and inherited predisposition to breast cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2517736122.
    PubMed         Abstract available
    
    

    
    Radiology

54. YOEN H, Shin HC, Yoon KH, Oh JH, et al
    Preoperative Breast MRI and Survival Outcomes in Women 50 Years or Younger with Breast Cancer.
    Radiology. 2025;317:e250439.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.